CoronaryAtlas logo
CoronaryAtlas
Anthranilic acid
Pathway / Myocardial injury (shared endpoint)

Anthranilic acid

metabolite

A tryptophan-derived metabolite elevated in STEMI that reflects kynurenine-pathway activation and myocardial ischemic injury.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencemedium
RationaleTryptophan catabolite linked to myocardial injury and inflammation in STEMI.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
20
C — non-Type-I
48
A — assay feasibility
42
E — evidence strength
17
T1DI (composite)
3
Specificity differential (R−C)-27.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum, plasma or urine
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container
Method / principle
LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available
Reagent / substrate
Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent
Platform
LC-MS/MS; some automated chemistry
Turnaround · availability
Send-out / research · Specialized / research

Literature evidence(1)